ミズーリ州における潰瘍性大腸炎の臨床試験
ミズーリ州内の拠点で、潰瘍性大腸炎に関する17件の研究が参加者を募集しています。
ミズーリ州内の都市
公式研究テキスト（英語）
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Specialists In Gastroenterology /ID# 283939, St Louis
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/10/01更新 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- SSM Health Medical Group, Bridgeton
- GI Associates Research, LLC, Columbia
- Mid America Gastro Intestinal Consultants, Kansas City
- 他1件
被験者募集中第4相
18歳〜80歳 · 全性別 · 2026/09/30更新 · NCT06581328A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-006, St Louis
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/29更新 · NCT07845487A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
- BVL Research - Kansas ( Site 1054), Liberty
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/28更新 · NCT07463183A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
- Washington University, St Louis
被験者募集中第2/3相
2歳〜17歳 · 全性別 · 2026/09/24更新 · NCT05076175Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Washington University School of Medicine, St Louis
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937086Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- University Health Truman Medical Center, Kansas City
- 他6件
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT03816345A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- KAD Clinical Research, St Louis
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/09/22更新 · NCT07483073A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Washington University School of Medicine, St Louis
被験者募集中第3相
2歳〜19歳 · 全性別 · 2026/09/22更新 · NCT04844606LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
- KAD Clinical Research, St Louis
- Specialists in Gastroenterology, St Louis
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/09/22更新 · NCT07415044A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- Mid-America Gastro-Intestinal Consultants, Kansas City
- BVL Clinical Research, Liberty
- Washington University School of Medicine, St Louis
被験者募集中第4相
18歳〜65歳 · 全性別 · 2026/09/21更新 · NCT06095128A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Gateway Gastroenterology - Site Number: 8400097, Chesterfield
- BVL Clinical Research - Site Number: 8400005, Liberty
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/09/15更新 · NCT07185009Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- BVL Research - Kansas ( Site 0292), Liberty
被験者募集中第3相
全年齢 · 全性別 · 2026/09/09更新 · NCT06651281An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Gateway Gastroenterology - Site Number: 8400097, Chesterfield
- BVL Clinical Research - Site Number: 8400005, Liberty
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/08/20更新 · NCT07184996BOOM-IBD2 Pivotal Clinical Trial
- Gateway GI Research (Objective Health), St Louis
被験者募集中
18歳〜85歳 · 全性別 · 2026/08/06更新 · NCT06571669A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
- Investigational Site Number: 8400014, St Louis
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/04/23更新 · NCT06975722A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Bridgeton
- Mirador Therapeutics Selected Site, Kansas City
- Mirador Therapeutics Selected Site, Liberty
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/03/12更新 · NCT07113522ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。